TITLE

On the Horizon

AUTHOR(S)
Karl, Elka
PUB. DATE
October 2004
SOURCE
Diabetes Health;Oct2004, Vol. 13 Issue 10, p74
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Presents a study on the effect of the combination of glucagon-like peptide (GLP-1) and Actos or pioglitazone on blood glucose levels. Treatments used in the study; Effect of GLP-1 monotherapy on insulin levels; Conclusion of the study.
ACCESSION #
15022848

 

Related Articles

  • Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness. Juhl, C. B.; Schmitz, O.; Pincus, S.; Holst, J. J.; Veldhuis, J.; Pørksen, N. // Diabetologia;May2000, Vol. 43 Issue 5, p583 

    Aims/hypothesis. The enteric incretin hormone, glucagon-like peptide-1 (GLP-1), is a potent insulin secretagogue in healthy humans and patients with Type II (non-insulin-dependent) diabetes mellitus. In this study we assessed the impact of short-term GLP-1 infusion on pulsatile insulin secretion...

  • Linagliptin linked to better blood sugar in black patients with type 2 diabetes. Costa, Samantha; Fisher, Stacey L.; Foster, Melissa // Endocrine Today;Jun2012, Vol. 10 Issue 6, p17 

    The article focuses on the effectiveness of linagliptin in improving the blood sugar levels of African American patients with type 2 diabetes, as discussed by researcher James Thrasher at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress...

  • Therapies for Diabetes: Pramlintide and Exenatide. Jones, Melissa C. // American Family Physician;6/15/2007, Vol. 75 Issue 12, p1831 

    The American Diabetes Association currently recommends an A1C goal of less than 7 percent. However, many patients are unable to achieve this goal by using oral drug combinations or diet and exercise, leaving insulin as the only treatment option. In most cases, insulin is initiated later in...

  • GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus. Legakis, Ioannis // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Nov2007, Vol. 1 Issue 3, p193 

    The gastrointestinal tract has a crucial role in the control of energy homeostasis through the action of multiple peptides known as incretins that act on distant target sites to promote the efficient uptake and storage of energy. In particular, GLP-1, an incretin hormone secreted from the...

  • Ileal Effect on Blood Glucose, HbA1c, and GLP-1 in Goto-Kakizaki Rats. Buchwald, Henry; Menchaca, Hector; Michalek, Van; Bertin, Nestor // Obesity Surgery;Nov2014, Vol. 24 Issue 11, p1954 

    Background: There have been enumerable studies on the effects of glucagon-like peptide-1 (GLP-1) on satiety and pancreatic islet function, stimulating the advocacy of surgical transposition of the ileum (rich in GLP-1-generating L-cells) higher in the gastrointestinal tract for earlier...

  • Basal Glucose Can Be Controlled, but the Prandial Problem Persists-It's the Next Target! Riddle, Matthew C. // Diabetes Care;Mar2017, Vol. 40 Issue 3, p291 

    Both basal and postprandial elevations contribute to the hyperglycemic exposure of diabetes, but current therapies are mainly effective in controlling the basal component. Inability to control postprandial hyperglycemia limits success in maintaining overall glycemic control beyond the first 5 to...

  • Oxyntomodulin Increases Insulin Secretion but Does Not Affect Insulin Sensitivity in High-Fat-Fed C57B1/6 Mice. Parlevliet, Edwin T.; Heijboer, Annemieke C.; Schröder-Van Der Elst, Janny P.; Havekes, Louis M.; Romijn, Johannes A.; Pijl, Hanno; Corssmit, Eleonora P. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA373 

    Gut-derived peptides like ghrelin and glucagon-like peptide (GLP-1) affect glucose metabolism in many ways, e.g. by altering insulin sensitivity or secretion. The proglucagon-derived peptide oxyntomodulin (OXM) is cosecreted with GLP-1 and inhibits feeding in rodents and man. We evaluated the...

  • Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver. Zheng, Dan; Ionut, Viorica; Mooradian, Vahe; Stefanovski, Darko; Bergman, Richard N. // Diabetes;Feb2009, Vol. 58 Issue 2, p352 

    OBJECTIVE--Recent progress suggests that exenatide, a mimetic of glucagon-likepeptide-1 (GLP-1), might lower glycemia independent of increased β-cell response or reduced gastrointestinal motility. We aimed to investigate whether exenatide stimulates glucose turnover directly in...

  • Differential GLP-1 Responses After Macronutrient Ingestion in Göttingen Minipigs. Larsen, Marianne O.; Ahrén, Bo; Deacon, Carolyn F.; Jelic, Katarina M.; Winzell, Maria S.; Carr, Richard D. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA670 

    The hypothesis that glucagon-like peptide-1 (GLP-1) is an important mediator of postprandial insulin secretion and glucose tolerance has been largely based on studies using oral glucose administration. Whether GLP-1 is also important after ingestion of other macronutrients has been little...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics